Is Lifyorli a chemotherapy drug?

Why do I only take it three times a week? The intermittent schedule is designed to maximize the “weakening” of cancer cells without causing excessive side effects.

Why do I only take it three times a week?

What does ‘Platinum-Resistant’ mean? It means the cancer returned within 6 months of finishing treatments like carboplatin or cisplatin.

What does ‘Platinum-Resistant’ mean?

Does it cause hair loss? Hair loss is common with the chemotherapy used alongside Lifyorli, but Lifyorli itself does not typically cause it.

Does it cause hair loss?

Is it a steroid? No. It is the opposite—it blocks the receptors that steroids (like cortisol) bind to.

Will insurance cover it? In April 2026, Lifyorli was added to the NCCN Guidelines, which usually triggers immediate coverage by US private insurers and Medicare.

Will insurance cover it?

Can I take it at home? Yes, the tablets are taken at home, but you must still visit the clinic for your weekly chemotherapy infusion.

Can I take it at home?

How long can I stay on it? Usually until the disease progresses or the side effects become too difficult to manage.

How long can I stay on it?

What if I vomit after taking my dose? In 2026, US guidelines suggest not taking an additional dose; wait until your next scheduled time.

What if I vomit after taking my dose?

Does it work for all ovarian cancers? It is specifically approved for the “platinum-resistant” stage. Your oncologist will run tests to see if you are a candidate.

Lifyorli (relacorilant) - Availability

Introduction

Lifyorli (relacorilant) is a first-in-class glucocorticoid receptor (GR) antagonist approved by the FDA in late March 2026. It is used in combination with nab-paclitaxel (Abraxane) to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. In the US, Lifyorli is being hailed as a “chemosensitizer.” It works by blocking the effects of cortisol, which cancer cells often use as a “shield” to survive chemotherapy. By removing this shield, Lifyorli allows the chemotherapy to effectively target and destroy the tumor.

Usage and Indications

In the US, Lifyorli is FDA-approved for:

Platinum-Resistant Ovarian Cancer: For patients who have received one to three prior systemic treatment regimens.
At least one of those prior treatments must have included bevacizumab (Avastin).
It is specifically indicated for those whose cancer has progressed within six months of completing platinum-based chemotherapy.

How to Take It (Dosage)

Form: Oral tablet.
Frequency: Taken in a specific “intermittent” schedule alongside chemotherapy.
Routine: In the 2026 US clinical protocol, Lifyorli is typically taken the day before, the day of, and the day after each weekly nab-paclitaxel infusion.
Administration: Tablets should be swallowed whole; do not crush or chew.

Side Effects

Because Lifyorli is used in combination with chemotherapy, side effects often reflect the combination of both drugs:

Common: Neutropenia (low white blood cell count), anemia, and fatigue.
Moderate: Nausea, abdominal pain, and peripheral neuropathy (numbness or tingling in hands/feet).
Specific to Lifyorli: Potential for electrolyte imbalances, specifically low potassium (hypokalemia).

Precautions and Warnings

Adrenal Insufficiency: Because Lifyorli blocks glucocorticoid receptors, it can mimic signs of adrenal insufficiency. Doctors monitor for extreme tiredness or low blood pressure.
Potassium Monitoring: US oncology teams check potassium levels frequently during treatment, as Lifyorli can cause levels to drop.
Reproductive Health: Lifyorli can cause fetal harm. Effective non-hormonal contraception is required during treatment and for several weeks after the last dose.

Interactions

Strong CYP3A Inhibitors/Inducers: Medications like certain antifungals or seizure meds can significantly change Lifyorli levels in the blood.
Hormonal Contraceptives: Lifyorli may decrease the effectiveness of hormonal birth control; “barrier methods” (like condoms) are recommended in the US 2026 guidelines.

Storage

Room Temperature: Store at 68°F to 77°F (20°C to 25°C).
Handling: As an oncology medication, it should be handled with care. If a tablet is broken, avoid direct skin contact or inhalation of the powder.

FAQ

Is Lifyorli a chemotherapy drug? No, it is a “receptor antagonist” that helps your chemotherapy work better. It is always taken with the chemo drug nab-paclitaxel.
Why do I only take it three times a week? The intermittent schedule is designed to maximize the “weakening” of cancer cells without causing excessive side effects.
What does ‘Platinum-Resistant’ mean? It means the cancer returned within 6 months of finishing treatments like carboplatin or cisplatin.
Does it cause hair loss? Hair loss is common with the chemotherapy used alongside Lifyorli, but Lifyorli itself does not typically cause it.
Is it a steroid? No. It is the opposite—it blocks the receptors that steroids (like cortisol) bind to.
Will insurance cover it? In April 2026, Lifyorli was added to the NCCN Guidelines, which usually triggers immediate coverage by US private insurers and Medicare.
Can I take it at home? Yes, the tablets are taken at home, but you must still visit the clinic for your weekly chemotherapy infusion.
How long can I stay on it? Usually until the disease progresses or the side effects become too difficult to manage.
What if I vomit after taking my dose? In 2026, US guidelines suggest not taking an additional dose; wait until your next scheduled time.
Does it work for all ovarian cancers? It is specifically approved for the “platinum-resistant” stage. Your oncologist will run tests to see if you are a candidate.